{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.07","upperLimit":"4.73","value":"4.27"},{"groupId":"OG001","lowerLimit":"1.68","upperLimit":"2.83","value":"2.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"PFS time was the elapsed time from the date of randomization to the first date of objective progression of disease or death from any cause. PFS was censored at the date of the participant's last tumor assessment for participants who were not known to have died or to have PD as of the data-inclusion cut-off date for analysis. PD, defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0), was at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed: 500 mg/m\\^2, IV administration, q 21 days, until disease progression.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG000","title":"Pemetrexed and BSC"},{"description":"Placebo: IV administration, q 21 days.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG001","title":"Placebo and BSC"}],"paramType":"MEDIAN","populationDescription":"Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 123, 36 participants in the pemetrexed and placebo treatment arms, respectively.","reportingStatus":"POSTED","timeFrame":"Randomization to measured PD or death from any cause (up to 41 months)","title":"Progression-Free Survival (PFS) Time","type":"PRIMARY","unitOfMeasure":"months"}